More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Existing-Home Sales Jump To Highest Level in 2-1/2 Years
- Paul: Audit the Fed
- Wave of Debt Payments Facing US Government
- TV Retailer QVC Joins 'Black Friday' Frenzy
- Start-Up Proves Everything Really Is Better With Bacon
- Buffett's Wealth and Fame Hasn't Helped 'Warren' As a Name
- Madoff—The Holiday Drink
- S&P Stocks Trading at New 52-Week Highs
- Nov. 23: Unusual Volume Leaders
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Rally Could 'Have Some Legs in 2010': Market Strategist
- Investors May Skew Housing Reality
- Buffett's Wealth and Fame Hasn't Helped 'Warren' As a Name
- Are Crazy Retail Deals Good for Business?
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- Wall Street 'Bonuses' Disappear—but Only in Name
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Even Buffett's Huge Fame Can't Help the Name 'Warren'
- Wave of Debt Payments Facing US Government
- JPMorgan's Dimon Could Succeed Geithner: Report
- Suze Orman’s 'A Healthier, Wealthier You'
- Maria Blog: Are Crazy Retail Deals Good for Business?
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
Rick Lee Heart Stent |
]drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4. The question now is whether the FDA will make a move before the July 4th holiday. Any bets?
Speaking of stents, a folo-up to my post last week on the analyst report saying that Boston Scientific [BSX
Loading...
()
]is discounting its drug-coated stent when they're bought along with other medical devices the company makes. At first, a BSX spokesman told me the company doesn't publicly talk about such alleged deals. But then Paul Donovan sent me another email last night asking in the subject line, "What were you smoking?" He took me to task for repeating "an unsubstantiated claim we're (BSX) selling stents for $1,100. We sell stents for about double that, and often more."
And as long as we're on the subject of corporate communications I wanted to pass along this anecdote about yesterday's Alzheimer's drug news out of Myriad Genetics[MYGN
Loading...
()
]. My producer, Ruth, had been working with their people to make sure we were in the loop when the biotech company released the highly anticipated late-stage test results. But the relationship-building groundwork was all for naught.
The press release went out before the opening bell on Monday, but we got no heads up or even an email once the release went out to make sure we saw it. I was out of pocket on assignment in Washington, DC, but reachable--as always--via BlackBerry. When Ruth queried the MYGN point-person about the oversight he replied, "We were planning personal outreach to you on positive results. Then when we found out the results were negative, no one thought to make sure you were on the email distribution list."
Oh, and I wasn't smoking anything when I wrote the BSX post. Aside from what I think was a contact high during my freshman year in the USC Trojan Marching Band on a bus returning from a gig, I've never inhaled.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes